ZURA | Zura Bio Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.57 - 3.74
52 Week Range	2.0000 - 7.22
Beta	0.55
Implied Volatility	N/A
IV Rank	47.95%
Day's Volume	194,015
Average Volume	330,591
Shares Outstanding	63,774,174
Market Cap	228,949,285
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-03-21

Valuation
Profitability
Growth
Health
P/E Ratio	6.30
Forward P/E Ratio	N/A
EPS	0.57
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	14
Country	USA
Website	ZURA

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

ZURA's peers: ABSI, ADPT, ALLR, ALT, ANNX, ARDX, ATNF, BNTC, CNTX, CRBP, CYTO, DRMA, DRUG, ELEV, ENSC, ENVB, EVAX, EXAI, FGEN, GERN, GOVX, HEPA, HOTH, IMMP, INAB, CYBN, IPA, JAGX, LEXX, LPCN, MEIP, NBTX, NBY, NCNA, NERV, NRBO, OCGN, ORMP, PALI, PHIO, PSTV, PYPD, PYXS, REVB, RIGL, RNAZ, SLS, SMMT, SNGX, TCBP, VIRI, VTVT, VYNE, XBIO, BIOR, CDIO, ERNA, SPRY, ZVSA, OCEA, CARM

*Chart delayed

Analyzing fundamentals for ZURA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ZURA Fundamentals page.

Watching at ZURA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ZURA Technicals page.